JPH0532371B2 - - Google Patents
Info
- Publication number
- JPH0532371B2 JPH0532371B2 JP58100315A JP10031583A JPH0532371B2 JP H0532371 B2 JPH0532371 B2 JP H0532371B2 JP 58100315 A JP58100315 A JP 58100315A JP 10031583 A JP10031583 A JP 10031583A JP H0532371 B2 JPH0532371 B2 JP H0532371B2
- Authority
- JP
- Japan
- Prior art keywords
- mps
- substance
- liver
- reaction
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000126 substance Substances 0.000 claims description 21
- 150000004676 glycans Chemical class 0.000 claims description 11
- 229920001282 polysaccharide Polymers 0.000 claims description 11
- 239000005017 polysaccharide Substances 0.000 claims description 11
- 208000004930 Fatty Liver Diseases 0.000 claims description 3
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 208000010706 fatty liver disease Diseases 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 8
- 235000000346 sugar Nutrition 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000000470 constituent Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 150000008163 sugars Chemical class 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 238000000862 absorption spectrum Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- JVIPLYCGEZUBIO-UHFFFAOYSA-N 2-(4-fluorophenyl)-1,3-dioxoisoindole-5-carboxylic acid Chemical compound O=C1C2=CC(C(=O)O)=CC=C2C(=O)N1C1=CC=C(F)C=C1 JVIPLYCGEZUBIO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 229920001425 Diethylaminoethyl cellulose Polymers 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108010046377 Whey Proteins Proteins 0.000 description 3
- 102000007544 Whey Proteins Human genes 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- AYJRCSIUFZENHW-UHFFFAOYSA-L barium carbonate Chemical compound [Ba+2].[O-]C([O-])=O AYJRCSIUFZENHW-UHFFFAOYSA-L 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229920001429 chelating resin Polymers 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- FNEHAOQZWPHONV-UHFFFAOYSA-N 9h-carbazole;sulfuric acid Chemical compound OS(O)(=O)=O.C1=CC=C2C3=CC=CC=C3NC2=C1 FNEHAOQZWPHONV-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 102000005840 alpha-Galactosidase Human genes 0.000 description 1
- 108010030291 alpha-Galactosidase Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- MMCPOSDMTGQNKG-UHFFFAOYSA-N anilinium chloride Chemical compound Cl.NC1=CC=CC=C1 MMCPOSDMTGQNKG-UHFFFAOYSA-N 0.000 description 1
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- AYJRCSIUFZENHW-DEQYMQKBSA-L barium(2+);oxomethanediolate Chemical compound [Ba+2].[O-][14C]([O-])=O AYJRCSIUFZENHW-DEQYMQKBSA-L 0.000 description 1
- 108010019077 beta-Amylase Proteins 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58100315A JPS59225120A (ja) | 1983-06-07 | 1983-06-07 | 脂肪肝生成抑制剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58100315A JPS59225120A (ja) | 1983-06-07 | 1983-06-07 | 脂肪肝生成抑制剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS59225120A JPS59225120A (ja) | 1984-12-18 |
| JPH0532371B2 true JPH0532371B2 (de) | 1993-05-14 |
Family
ID=14270743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58100315A Granted JPS59225120A (ja) | 1983-06-07 | 1983-06-07 | 脂肪肝生成抑制剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS59225120A (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2764267B2 (ja) * | 1988-04-20 | 1998-06-11 | 雪印乳業株式会社 | 胆汁酸分泌促進作用を有する機能性飲食品 |
| US8821853B2 (en) | 2006-07-25 | 2014-09-02 | Megmilk Snow Brand Co., Ltd. | Anti-fatty liver agent |
| JP5247012B2 (ja) | 2006-07-25 | 2013-07-24 | 雪印メグミルク株式会社 | 脂肪肝抑制剤 |
| AU2009220403B2 (en) * | 2008-03-07 | 2015-02-26 | Megmilk Snow Brand Co., Ltd. | Agents for promoting secretion and/or suppressing decrease of adiponectin |
| JP5804542B2 (ja) * | 2010-03-25 | 2015-11-04 | 雪印メグミルク株式会社 | 脂肪肝予防及び／又は抑制剤 |
| EP2668851B1 (de) | 2012-05-29 | 2016-03-23 | Ueno Fine Chemicals Industry, Ltd. | Leberfunktion verbesserndes Mittel |
-
1983
- 1983-06-07 JP JP58100315A patent/JPS59225120A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS59225120A (ja) | 1984-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH0728694B2 (ja) | 整腸作用を有する食品組成物 | |
| Auricchio et al. | Isomaltose intolerance causing decreased ability to utilize dietary starch | |
| JPS6216638B2 (de) | ||
| US5939309A (en) | Bifidobacterium bifidum proliferation promoting composition containing xylooligosaccharide | |
| JP2001302523A (ja) | Ｌｄｌ酸化抑制飲食品及び医薬品 | |
| JPH0532371B2 (de) | ||
| JP2928335B2 (ja) | 抗高血圧剤および飲食品 | |
| JP4054697B2 (ja) | 便秘改善剤 | |
| JPH10130160A (ja) | 脂質代謝改善剤及びそれを含有する食品 | |
| JPH0940566A (ja) | 乳酸菌発酵物からなる糖尿病治療剤及び免疫増強剤 | |
| HU191697B (en) | Process for preparing a new polysaccharide decreasing triglyceride blood level and pharmaceutical compositions containing thereof | |
| JPS6133840B2 (de) | ||
| KR100302505B1 (ko) | 유산균 발효액 및 이를 함유하는 화장료 조성물 | |
| JPS6316118B2 (de) | ||
| JPH058173B2 (de) | ||
| Sloven et al. | Hydrolysis and absorption of glucose polymers from rice compared with corn in chronic diarrhea of infancy | |
| JP2855283B2 (ja) | 抗潰瘍剤およびその製造法 | |
| JPH0859492A (ja) | 抗糖尿病薬 | |
| JPH0899888A (ja) | グルタチオンペルオキシダーゼ活性化剤 | |
| JPH06116156A (ja) | 血糖値低下剤 | |
| AU774675B2 (en) | Compositions and methods for human gastrointestinal health | |
| JPS601877B2 (ja) | 高分子多糖類物質ｍｐｓ−８０及びその製造法 | |
| CN114391648B (zh) | 一种具有降血糖降血脂功效的益生菌发酵燕麦组合物的制备方法 | |
| JPH09132533A (ja) | 乳酸菌発酵物からなる潰瘍抑制剤及び肝臓障害抑制剤 | |
| JP2841237B2 (ja) | 血圧降下作用を有する菌体水抽出物を有効成分とする血圧降下剤 |